Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103295 | 0.92 | SFRP1 (0.75) | SFRP1ALDH1A1PPARGPOLBMEN1 | |
| SCHEMBL6103073 | 0.91 | SFRP1 (0.61) | SFRP1ALDH1A1SMN1; SMN2PPARGPOLB | |
| SCHEMBL4617536 | 0.91 | SFRP1 (0.67) | SFRP1ALDH1A1SMN1; SMN2POLBMEN1 | |
| SCHEMBL4618783 | 0.90 | SFRP1 (0.80) | SFRP1ALDH1A1SMN1; SMN2POLBAKR1C3 | |
| SCHEMBL4617298 | 0.89 | SFRP1 (0.62) | SFRP1ALDH1A1SMN1; SMN2PPARGPOLB | |
| SCHEMBL4617591 | 0.89 | ALDH1A1 (0.72) | SFRP1ALDH1A1SMN1; SMN2POLBMEN1 | |
| SCHEMBL6102121 | 0.89 | ALDH1A1 (0.58) | SFRP1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4616990 | 0.89 | SFRP1 (0.70) | SFRP1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4618988 | 0.89 | SFRP1 (0.70) | SFRP1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4618307 | 0.89 | SFRP1 (0.64) | SFRP1ALDH1A1SMN1; SMN2PPARGPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885ALDH1A1 1865/4885SMN1; SMN2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.